Trial Shows Treatment-Resistant Advanced Non-Small Cell Lung Cancer Responds To Rociletinib

Share this content:
Trial shows treatment-resistant advanced non-small cell lung cancer responds to rociletinib
Trial shows treatment-resistant advanced non-small cell lung cancer responds to rociletinib
A new drug that targets not only common cancer-causing genetic mutations in patients with non-small cell lung cancer (NSCLC), but also a form of the mutation that causes resistance to treatment, has shown promising results in patients in a phase I/II clinical trial. The research will be presented today (Friday) at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
READ FULL ARTICLE From Medical Express
Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

is free, fast, and customized just for you!




Already a member?

Sign In Now »